Søgning
Søgning på udtrykket 'hepatitis' giver 65 resultater
Dokumenter [17]
Sider [4]
Kalender [2]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Diagnostik, behandling og forebyggelse af infektion med hepatitis A virus (HAV)
Udarbejdet af arbejdsgruppe fra Dansk Selskab for Infektionsmedicin og Dansk Fertilitetsselskab.
National guideline udarbejdet af en arbejdsgruppe nedsat af medlemmer fra Dansk Selskab for Infektionsmedicin og medlemmer fra Dansk Selskab for Gastroenterologi og Hepatologi.
Version 9.
Udarbejdet af en arbejdsgruppe nedsat af Dansk Selskab for Infektionsmedicin og Dansk Selskab for Gastroenterologi og Hepatologi.
Omhandler biologiske og målrettede syntetiske lægemidler (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner.
Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Se.
Udarbejdet af en arbejdsgrupper bestående af medlemmer fra Dansk Selskab for Infektionsmedicin og Dansk Transplantationsselskab
Om håndtering og opfølgning for at minimere risiko for smitte med bl.a. HIV, HBV og HCV.
Bl.a. om HIV, hepatitis, resistente bakterier og immundefekt
Bl.a. om HIV, hepatitis, influenza og CNS infektioner
Bl.a. om HIV, hepatitis, cystisk fibrose og nye guidelines
Bl.a. om hepatitis, emerging viruses og immundefekt
Bl.a. om sygdom efter udlandsrejse, resistens og kroniske virale infektioner
Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)
Krogh-Madsen, Toke Barfod, Ulla Balslev, Hanne Arildsen, Lotte Ebdrup, Lars Toft Nielsen, Jon Holler
Gastrointestinale infektioner:
Karina Frahm Kirk (tovholder), Morten Helms, Merete Storgaard, Janne Fuglsang Hansen, Mike Zangenberg
Hepatitis:
Akut viral hepatitis:
Carsten Shade Larsen (tovholder) og Nina Weis.
ogram.
Afventer
Sted.
Aalborg Universitets Hospital
Delkursusledelse.
Jakob Bodilsen og Lars Omland
Tidligere kurser.
19. og 20. september 2024
9. og 10 september 2021
11. og 12. april 2018
Gastroenterologiske infektioner og kronisk hepatitis:
Dato for næste kursus
2026:
Sted.
Odense Universitetshospital
Delkursusledelse.
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser.
4. og 5. december 2023
3. og 4.
ogiske oversigter (slides).
www.natap.org/. National AIDS Treatment Advocacy Project ? en New York State non-profit NGO ledet af Jules Levin (som selv lever med Hiv og hepatitis). God side, hvis man mangler slides/figurer/tabeller fra studier præsenteret på senest afholdte konferencer kommer ofte med referat (inklusive Jules Levins fortolkning ud fra et patient/aktivist perspektiv).
www.clinicaloptions.com/HIV.aspx. Et andet website for opdateringer og sammendrag af konferencer (slides).
Professor Henrik Nielsen kommenterer: I disse år sker et paradigmeskift i behandlingen af kronisk hepatitis C virus infektionen. Mange direkte virkende lægemidler er i afprøvning og med lovende resultater. Snart er interferon-baseret terapi ikke absolut nødvendig, mens oral terapi af kort varighed synes indenfor rækkevidde. Samtidigt er bivirkninger ved de nye lægemidler hidtil beskrevet som milde og sjældne.
Professor Nina Weis kommenterer: Kronisk hepatitis B, forårsaget af forekomst af hepatitis B virus i blodet i > 6 måneder, kan klinisk manifestere sig fra asymptomatisk til fibrose, cirrose og hepatocellulært carcinom.
Trods forekomst af en effektiv vaccine i mere end 40 år, lever 296 millioner mennesker globalt med kronisk hepatitis B, heraf estimerede 14.500 i Danmark.
4. juni, Barcelona, Spanien
4. juni, Barcelona, Spanien
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Journal of Medical Virology
19.02.2025
Journal of Medical Virology, Volume 97, Issue 2, February 2025.
Journal of Infectious Diseases
19.02.2025
Abstract . Background . Individuals who do not match any specific stage in the natural history of chronic hepatitis B are classified into the grey-zone, and appropriate management for these patients remains unclear. This study aimed to develop and validate a non-invasive model to identify grey-zone patients requiring antiviral therapy (AVT).Methods .
Infection
15.02.2025
. Abstract. . Background. Acute hepatitis E infection (HEV), with its high incidence in Europe, should be considered as a differential diagnosis of acute viral hepatitis and can in some cases manifest with pronounced neurological symptoms. . . . Clinical Case.
Clinical Infectious Diseases
13.02.2025
To the Editor—We read with real interest the study by Biondi et al [1] analyzing the disparities of care of hepatitis C virus infection in reproductive-aged women with opioid use disorder. The authors conclude by calling for interventions to improve overall rates and equity in hepatitis C virus screening and treatment for women of reproductive age and highlight the negative impact of racial and ethnic disparities.
Journal of Medical Virology
12.02.2025
Journal of Medical Virology, Volume 97, Issue 2, February 2025.
Antimicrobial Agents And Chemotherapy
5.02.2025
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Journal of the American Medical Association
4.02.2025
This noninferiority randomized clinical trial investigates whether administering tenofovir to pregnant individuals with hepatitis B virus beginning at gestational week 16 is noninferior to administering tenofovir beginning at gestational week 28 in preventing mother-to-child transmission.
BMC Infectious Diseases
2.02.2025
. Abstract. . Background. Hepatitis B-associated cirrhosis (HBC) is associated with severe complications and adverse clinical outcomes. This study aimed to develop and validate a predictive model for the occurrence of multiple complications (three or more) in patients with HBC and to explore the effects of multiple complications on HBC prognosis. . . . Methods.
BMC Infectious Diseases
1.02.2025
. Abstract. . Background. Hepatitis B virus (HBV) infection is associated with hepatitis, often progressing to liver cirrhosis or cancer, posing a significant public health challenge, particularly in Thailand. Previous research revealed that viral causes account for 18.5% of acute undifferentiated febrile illness (AUFI) in Asian countries.
BMC Infectious Diseases
1.02.2025
. Abstract. . Background. Human hepatitis is an inflammation of the liver brought on by the DNA virus known as the hepatitis B virus (HBV). Around the world, 240 million people are thought to have HBV in a chronic state. The prevalence of viral hepatitis is extremely high in Africa. Prior reports from various regions of the nation have indicated a variable prevalence of HBV infection. . .
BMC Infectious Diseases
1.02.2025
e in Uganda. Patients with HBV do not receive routine counselling and education, and there are limited resources for laboratory investigation coupled with a high loss to follow-up. This study set out to assess barriers and facilitators of integrated viral hepatitis B C and HIV care model to optimize screening uptake among mothers and newborns at health facilities in Koboko District, west Nile sub-region, Uganda. . . . Methods.
Clinical Infectious Diseases
31.01.2025
Abstract . Sofosbuvir/velpatasvir/voxilaprevir is recommended for hepatitis C virus (HCV) retreatment in those who fail initial treatment but is unavailable in resource-limited settings. We describe a government sofosbuvir/velpatasvir + ribavirin (SOF/VEL + RBV) × 24 weeks retreatment program in Rwanda (November 2021–October 2022). Of 231 participants, 174 were cured (75.3% intention-to-treat analysis). SOF/VEL + RBV may be considered for HCV retreatment in resource-limited settings.
BMC Infectious Diseases
30.01.2025
e in Uganda. Patients with HBV do not receive routine counselling and education, and there are limited resources for laboratory investigation coupled with a high loss to follow-up. This study set out to assess barriers and facilitators of integrated viral hepatitis B C and HIV care model to optimize screening uptake among mothers and newborns at health facilities in Koboko District, west Nile sub-region, Uganda. . . . Methods.
Journal of the American Medical Association
29.01.2025
Hepatitis B virus (HBV) infection continues to pose a significant global health challenge despite the availability of effective vaccines for more than 4 decades and antivirals for almost 3 decades. The World Health Organization estimates that more than 254 million people worldwide are living with chronic HBV infection; 1.2 million new infections occurred in 2022.
Journal of Medical Virology
28.01.2025
Journal of Medical Virology, Volume 97, Issue 2, February 2025.
BMC Infectious Diseases
25.01.2025
. Abstract. . Background. Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts.
BMC Infectious Diseases
23.01.2025
. Abstract. . Background. Kyrgyzstan introduced universal hepatitis B childhood vaccination in 1999 to reduce the burden of hepatitis B. In 2016, aligned with the goal of controlling hepatitis B in the WHO European Region, a regional target of 0.5% was set for seroprevalence of hepatitis B surface antigen (HBsAg) among targeted birth cohorts.
PLoS One Infectious Diseases
17.01.2025
by Ajit Patil, Pallavi Vidhate, Sandip Patil, Amrita Rao, Swarali Kurle, Samiran Panda . Viral hepatitis is a major public health challenge. Hepatitis C Virus (HCV) infection causes the progressive liver damage.
BMC Infectious Diseases
17.01.2025
. Abstract. . Background. Hepatitis A remains a public health concern, particularly in areas with suboptimal sanitation. Introduced in Turkey's immunization schedule in 2011, the vaccine has improved immunity; however, gaps persist, especially in older, unvaccinated children.
Clinical Infectious Diseases
15.01.2025
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
ProMED
16.02.2025
. . .
HEPATITIS A - USA (03): (NEW YORK CITY) RESTAURANT, INFECTED FOOD. HANDLER. *************************************************************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Fri 14 Feb 2025 . Source: Food Poisoning News [edited] .
www.foodpoisoningnews.com/hepatitis-a-alert-issued-for-manhattan-restaurant/ . . .
ProMED
9.02.2025
. . .
HEPATITIS A - USA (02): (WISCONSIN) UNIVERSITY DINING HALL, INFECTED. FOOD HANDLER. *********************************************************************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Fri 7 Feb 2025 17:46 CST . Source : Daily Cardinal [edited] .
ProMED
24.01.2025
. . .
HEPATITIS A - SPAIN: 2024 INCREASE. **********************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Sun 29 Dec 2024 . Source: Esto ES [in Spanish, machine trans., edited] .
www.estoesdxt.es/espana-enfrenta-el-mayor-aumento-de-hepatitis-a-en-una-decada-894-casos-en-2024/ . . . Spain faces largest increase in
hepatitis A in a decade: 894 cases in.
ProMED
20.01.2025
. . .
HEPATITIS C - PAKISTAN: INCREASED NUMBERS. *****************************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Sun 12 Jan 2025 . Source: The Dawn [edited] .
www.dawn.com/news/1884593/pakistan-tops-world-in-hepatitis-c-cases-pms-aide . . . Pakistan tops world in
hepatitis C cases: PM's aide . --------------------------------------------- .
ProMED
20.01.2025
. . .
HEPATITIS A - USA: (COLORADO) INFECTED FOOD HANDLER. ***************************************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Wed15 Jan 2025 . Source: Food Poisoning Bulletin [edited] .
foodpoisoningbulletin.com/2025/possible-hepatitis-a-exposure-at-rio-grande-in-boulder-co/ . . . Possible
hepatitis A exposure at Rio Grande in Boulder, CO .
ProMED
15.01.2025
. . .
HEPATITIS A - NETHERLANDS: FROZEN BLUEBERRIES, ALERT, RECALL. ************************************************************. A ProMED-mail post.
www.promedmail.org. ProMED-mail is a program of the. International Society for Infectious Diseases.
www.isid.org . Date: Tue 14 Jan 2025 . Source: NL Times [edited] .
nltimes.nl/2025/01/14/hundreds-hepatitis-infections-will-tied-blueberries-albert-heijn-recall . . .
Morbidity and Mortality Weekly Report (MMWR)
5.12.2024
This report describes an update to the recommendation for Hepatitis B vaccination in adults aged 19-59 years.
Eurosurveillance latest updates
15.11.2024
. Background. Hepatitis C virus (HCV) infection is targeted for elimination as a public health threat by 2030. The World Health Organization goal for treatment uptake is ≥ 80% among cases diagnosed with an active HCV infection (RNA- or core antigen-positive), maintained for 2 years. . . Aim. To calculate treatment uptake, time from diagnosis to treatment start and complete treatment dispensation among notified cases of HCV infection in Norway. . . Method.
Eurosurveillance latest updates
8.11.2024
. Background. Recent hepatitis A virus outbreaks in Europe affecting men who have sex with men (MSM) and ongoing hepatitis B virus transmission among MSM underscore the ongoing need for viral hepatitis prevention in this population. . . Aim. To describe viral hepatitis knowledge and associated factors among MSM in the WHO European Region to inform targeted prevention. . . Methods.
Eurosurveillance latest updates
8.11.2024
. Background. Hepatitis A and B vaccinations are recommended for men who have sex with men (MSM), given their increased risk of infection. However, data on vaccination programmes are scarce. . . Aim. To use information on vaccination recommendations and vaccine uptake among MSM in the WHO European Region to guide prevention. . . Methods.
Medscape Infectious Diseases
7.11.2024
The rate of HCV reinfection was high in the immediate posttreatment period among individuals who injected drugs but decreased significantly over time. . Medscape Medical News
Eurosurveillance latest updates
26.10.2024
. Background. Hepatitis E, a viral hepatitis caused mainly by the ingestion of raw or undercooked food, is not a notifiable disease in Spain. . . Aim. To analyse the temporal trends, epidemiological characteristics and factors associated with severe disease from hepatitis E hospitalisations in Spain from 1997 to 2019. . . Methods. Hospitalisation records were obtained from the Spanish National Hospital Discharge Database.
Medscape Infectious Diseases
28.09.2024
The study highlighted that 57.7% of neonates in the case group had a diagnosis of neonatal abstinence syndrome compared to 10.0% in the control group. . Medscape Medical News
Medscape Infectious Diseases
31.08.2024
The rules about whom to screen and vaccinate for hepatitis B are now more clinician-friendly. . The Curbsiders
Morbidity and Mortality Weekly Report (MMWR)
2.08.2024
This report describes progress toward eliminating hepatitis B and C in the country of Georgia.
Medscape Infectious Diseases
29.07.2024
This requires sensitivity to stigmas and awareness of hepatitis B and C prevalence in local communities. . Medscape Medical News
Eurosurveillance latest updates
26.07.2024
. Introduction. Obtaining epidemiological data on chronic hepatitis C virus (HCV) infection is essential to monitor progress towards the hepatitis C elimination targets. . . Aim. We aimed to estimate the prevalence of chronic HCV and the seroprevalence of HCV in the adult general population in Estonia. . . Methods.
Eurosurveillance latest updates
26.07.2024
. Introduction. A national study from 2006 to 2008 showed a high antibody prevalence of 3.2% against hepatitis C virus (HCV) in Romania, but more recent epidemiological data on hepatitis C prevalence are lacking. . . Aim. We aimed to estimate the current prevalence of HCV antibodies (anti-HCV) and chronic HCV infection in the general adult population in Romania, as a crucial element in monitoring progress towards eliminating hepatitis C. . . Methods.